Treatment of Hereditary C1 Inhibitor Deficiency During Pregnancy and Breastfeeding
Hereditary C1 inhibitor deficiency requires careful therapy selection when the patient is pregnant or breastfeeding. Both situations call for an approach that accounts for the safety of the patient and the developing or nursing infant.
Clinical Scenario
This protocol applies to patients with hereditary C1 inhibitor deficiency who are pregnant or breastfeeding (lactating). This is a first-line protocol — no prior treatment failure is required.
Treatment Approach
A plasma-derived C1 inhibitor preparation is used as the first-line therapeutic option in this setting. The complete protocol — including dosing, clinical algorithm, and monitoring guidance — is available via the structured regimen below.
Full regimen detail, dosing, and decision algorithm are in the structured protocol.
References
- We recommend plasma-derived C1 inhibitor as the preferred therapy during pregnancy and lactation
- C1-INH is recommended as first-line therapy for pregnant or breastfeeding HAE-1/2 patients as it is safe and effective.
DOI: 10.1111/all.15214
View source ↗